Medical weight loss programs, like the ones offered at The Remedy Realm, are designed and supervised by medical professionals who specialize in weight management. These programs take into account your unique health profile, including any underlying medical conditions or medications, to create a personalized approach that addresses the root causes of weight gain.

The timeframe for seeing results can vary depending on the specific treatment, your individual health profile, and your adherence to the recommended plan. Some patients may start noticing improvements within a few weeks, while others may require longer. During your consultation, Dr. Schreiber will provide you with realistic expectations and a general timeline based on your unique circumstances.

There are no refunds for services provided. We aim for the satisfaction of our clients. If you have any concerns please reach out so we can address them.

For a requested at-home appointment, there is no charge if canceled more than ninety minutes before the appointment. If the appointment is canceled within 90 minutes then there is a $150 non-refundable fee.

The FDA-approved brand name drugs, such as Wegovy® and Ozempic® are exclusively available from the Novo Nordisk™ company. Mounjaro™ is exclusively available from Eli Lilly and Company™. The Remedy Realm does not claim any affiliation with, or endorsement from, the above mentioned products or entities. We do not offer any of the above mentioned products, anyone seeking said products should discuss options with their licensed healthcare provider or pharmacist. The Remedy Realm exclusively offers compounded medications, which are made in State Board of Pharmacy licensed sterile compounding pharmacies, or FDA-licensed 503(b) Outsourcing Facilities. While these facilities are strictly regulated, the compounded medications they make are not FDA-approved, as they are compounded based on an individual provider’s prescription for a specified patient. Strength, dose, route of administration, and other variables may make compounded medications different from FDA-approved drugs which makes directly comparing results & risk profile between FDA-approved drugs and compounded drugs difficult. Any compounded drugs prescribed are based on a licensed provider’s medical judgement based on a telehealth encounter and medical history.

Our prices are geared to save you more than you would purchasing the medications at MSRP and even at coupon offerings. We do not accept or participate with insurance.

We provide transparent pricing clear pricing information during your consultation. We strive to make our treatments as accessible as possible and we are priced well below that of MSRP with or without coupons.

Membership fees cover everything you will need. It includes provider consultation, medication and syringes.The membership subscription fee for Compounded Semaglutide is just $45* a week ($449 Paid every 10 weeks). Compounded Tirzepatide subscription is just $112* a month ($449 Paid every 4 weeks). Retatrutide treatment starts at $899 a month

After your provider has prescribed a GLP-1 medication we send the prescription to a compounding pharmacy. The pharmacy hours are normal weekday business hours. Any prescriptions placed outside normal business hours such as late on a Friday will only first be processed on Monday morning (provided it is not a holiday). Overall, most clients receive their medication within 8-10 business days* from when they speak to their provider. Please note, clients in California may experienced increased fulfillment time due to additional compound testing.

*business days do not include weekends or holidays and are not included in the count of expected days

All three medications are in the GLP-1 family.

Semaglutide has activity only as GLP-1 and is therefore a medication with singular activity.

Tirzepatide has activity as GLP-1 AND GIP. It is therefore known as a dual activity medication and it is felt to have enhanced desirable effects.

Retatrutide, the newest in this class has activity as GLP-1, GIP AND Glucagon receptors, giving this newest medication greater effect utilizing three activities of the cell receptors.

All three medications are in the GLP-1 family.

Semaglutide has activity only as GLP-1 and is therefore a medication with singular activity.

Tirzepatide has activity as GLP-1 AND GIP. It is therefore known as a dual activity medication and it is felt to have enhanced desirable effects.

Retatrutide, the newest in this class has activity as GLP-1, GIP AND Glucagon receptors, giving this newest medication greater effect utilizing three activities of the cell receptors.